 | Up a level |
Mastall, Maximilian; Roth, Patrick; Bink, Andrea; Fischer Maranta, Angela; Läubli, Heinz; Hottinger, Andreas Felix; Hundsberger, Thomas; Migliorini, Denis; Ochsenbein, Adrian; Seystahl, Katharina; Imbach, Lukas; Hortobagyi, Tibor; Held, Leonhard; Weller, Michael; Wirsching, Hans-Georg (2024). A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol. BMC cancer, 24(1) BioMed Central 10.1186/s12885-023-11797-z
Esposito, Roberta; Lanzós, Andrés; Uroda, Tina; Ramnarayanan, Sunandini; Büchi, Isabel; Polidori, Taisia; Guillen-Ramirez, Hugo; Mihaljevic, Ante; Merlin, Bernard Mefi; Lia, Mela; Zoni, Eugenio; Hovhannisyan, Lusine; McCluggage, Finn; Medo, Matúš; Basile, Giulia; Meise, Dominik F; Zwyssig, Sandra; Wenger, Corina; Schwarz, Kyriakos; Vancura, Adrienne; ... (2023). Tumour mutations in long noncoding RNAs enhance cell fitness. Nature communications, 14(1), p. 3342. Nature Publishing Group 10.1038/s41467-023-39160-7
Zens, Philipp; Bello, Corina Manuela; Scherz, Amina; von Gunten, Michael; Ochsenbein, Adrian; Schmid, Ralph A; Berezowska, Sabina (2022). The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer. Modern pathology, 35(12), pp. 1848-1859. Springer Nature 10.1038/s41379-022-01139-y
Deng, Haibin; Gao, Yanyun; Trappetti, Verdiana; Hertig, Damian; Karatkevich, Darya; Losmanová, Tereza; Urzì, Christian; Ge, Huixiang; Geest, Gerrit Adriaan; Bruggmann, Remy; Djonov, Valentin; Nuoffer, Jean-Marc; Vermathen, Peter; Zamboni, Nicola; Riether, Carsten; Ochsenbein, Adrian; Peng, Ren-Wang; Kocher, Gregor Jan; Schmid, Ralph; Dorn, Patrick; ... (2022). Targeting lactate dehydrogenase B-dependent mitochondrial metabolism affects tumor initiating cells and inhibits tumorigenesis of non-small cell lung cancer by inducing mtDNA damage. Cellular and molecular life sciences, 79(8), p. 445. SP Birkhäuser Verlag Basel 10.1007/s00018-022-04453-5
Zens, Philipp; Bello, Corina; Scherz, Amina; Koenigsdorf, Julia; Pöllinger, Alexander; Schmid, Ralph A.; Ochsenbein, Adrian; Neppl, Christina; Langer, Rupert; Berezowska, Sabina Anna (2021). A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response. Modern pathology, 34(7), pp. 1333-1344. Springer Nature 10.1038/s41379-021-00777-y
Riether, Carsten; Radpour, Ramin; Kallen, Nils M.; Bürgin, Damian T.; Bachmann, Chantal; Schürch, Christian M.; Lüthi, Ursina; Arambasic, Miroslav; Hoppe, Sven; Albers, Christoph E.; Baerlocher, Gabriela M.; Ochsenbein, Adrian (2021). Metoclopramide treatment blocks CD93-signaling-mediated self-renewal of chronic myeloid leukemia stem cells. Cell reports, 34(4), p. 108663. Cell Press 10.1016/j.celrep.2020.108663
Wirsching, Hans-Georg; Roelcke, Ulrich; Weller, Jonathan; Hundsberger, Thomas; Hottinger, Andreas F; von Moos, Roger; Caparrotti, Francesca; Conen, Katrin; Remonda, Luca; Roth, Patrick; Ochsenbein, Adrian; Tabatabai, Ghazaleh; Weller, Michael (2021). MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. Clinical cancer research, 27(1), pp. 179-188. American Association for Cancer Research 10.1158/1078-0432.CCR-20-2096
Kollár, Attila; Bütikofer, Lukas; Ochsenbein, Adrian; Stettler, Christoph; Trepp, Roman (2020). Treatment sequence in patients with neuroendocrine tumours: a nationwide multicentre, observational analysis of the Swiss neuroendocrine tumour registry. Swiss medical weekly, 150, w20176. EMH Schweizerischer Ärzteverlag 10.4414/smw.2020.20176
Salomé, Bérengère; Gomez-Cadena, Alejandra; Loyon, Romain; Suffiotti, Madeleine; Salvestrini, Valentina; Wyss, Tania; Vanoni, Giulia; Ruan, Dan Fu; Rossi, Marianna; Tozzo, Alessandra; Tentorio, Paolo; Bruni, Elena; Riether, Carsten; Jacobsen, Eva-Maria; Jandus, Peter; Conrad, Curdin; Hoenig, Manfred; Schulz, Ansgar; Michaud, Katarzyna; Della Porta, Matteo Giovanni; ... (2019). CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. Blood advances, 3(22), pp. 3674-3687. American Society of Hematology 10.1182/bloodadvances.2018030478
Al Sayed, M; Amrein, Martin Lukas; Bührer, Emanuel; Huguenin, AL; Radpour, Ramin; Riether, Carsten; Ochsenbein, Adrian (2019). T-cell-Secreted TNFα Induces Emergency Myelopoiesis and Myeloid-Derived Suppressor Cell Differentiation in Cancer. Cancer research, 79(2), pp. 346-359. American Association for Cancer Research AACR 10.1158/0008-5472.CAN-17-3026
Radpour, Ramin; Riether, Carsten; Simillion, Cedric; Höpner, Sabine; Bruggmann, Rémy; Ochsenbein, Adrian (2019). CD8+ T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia. Leukemia, 33(10), pp. 2379-2392. Nature Publishing Group 10.1038/s41375-019-0441-9
Tièche, Colin; Gao, Yanyun; Bührer, Elias; Hobi, Nina; Berezowska, Sabina Anna; Wyler, Kurt; Froment, Laurène; Weis, Stefan; Peng, Ren-Wang; Bruggmann, Rémy; Schär, Primo; Amrein, Michael Alex; Hall, Sean; Dorn, Patrick; Kocher, Gregor; Riether, Carsten; Ochsenbein, Adrian; Schmid, Ralph; Marti, Thomas (2019). Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549. Neoplasia, 21(2), pp. 185-196. Elsevier 10.1016/j.neo.2018.09.008
Shun-Qing, Liang; Bührer, Elias; Berezowska, Sabina Anna; Marti, Thomas; Xu, Duo; Froment, Laurène; Yang, Haitang; Hall, Sean; Vassella, Erik; Zhang, Yang; Kocher, Gregor; Amrein, Michael Alex; Riether, Carsten; Ochsenbein, Adrian; Schmid, Ralph; Peng, Ren-Wang (2019). mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. Oncogene, 38(5), pp. 622-636. Nature Publishing Group 10.1038/s41388-018-0479-6
Al Sayed, Mohamad; Ruckstuhl, Carla Alicia; Hilmenyuk, Tamara; Claus, Christina; Bourquin, Jean-Pierre; Bornhauser, Beat C; Radpour, Ramin; Riether, Carsten; Ochsenbein, Adrian (2017). CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies. Blood, 130(3), pp. 297-309. American Society of Hematology 10.1182/blood-2016-12-756585
Gautschi, Oliver; Rothschild, Sacha I; Li, Qiyu; Matter-Walstra, Klazien; Zippelius, Alfred; Betticher, Daniel C; Früh, Martin; Stahel, Rolf A; Cathomas, Richard; Rauch, Daniel; Pless, Miklos; Peters, Solange; Froesch, Patrizia; Zander, Thilo; Schneider, Martina; Biaggi, Christine; Mach, Nicolas; Ochsenbein, Adrian (2017). Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clinical lung cancer, 18(3), pp. 303-309. Elsevier 10.1016/j.cllc.2016.11.007
Zysset, Daniel; Weber, Benjamin; Rihs, Silvia; Brasseit, Jennifer; Freigang, Stefan Bernd; Riether, Carsten; Banz Wälti, Yara; Cerwenka, Adelheid; Simillion, Cedric; Marques-Vidal, Pedro; Ochsenbein, Adrian; Saurer, Leslie; Müller, Christoph (2016). TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis. Nature communications, 7(13151), p. 13151. Nature Publishing Group 10.1038/ncomms13151
Gautschi, O; Li, Q; Matter-Walstra, K; Betticher, D; Frueh, M; Rauch, Daniel; Pless, M; Froesch, P; Mach, N; Ochsenbein, Adrian (2016). 143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial. Journal of thoracic oncology, 11(4Suppl), S120-S120. Elsevier 10.1016/S1556-0864(16)30253-2
Gross, Stefanie; Lennerz, Volker; Gallerani, Elisa; Mach, Nicolas; Böhm, Steffen; Hess, Dagmar; von Boehmer, Lotta; Knuth, Alexander; Ochsenbein, Adrian; Gnad-Vogt, Ulrike; Forssmann, Ulf; Woelfel, Thomas; Kaempgen, Eckhart (2016). Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers. Cancer immunology research, 4(1), pp. 18-25. American Association for Cancer Research 10.1158/2326-6066.CIR-15-0105
Stahel, Rolf A; Riesterer, Oliver; Xyrafas, Alexandros; Opitz, Isabelle; Beyeler, Michael; Ochsenbein, Adrian; Früh, Martin; Cathomas, Richard; Nackaerts, Kristiaan; Peters, Solange; Mamot, Christoph; Zippelius, Alfred; Mordasini, Carlo; Caspar, Clemens B; Eckhardt, Katrin; Schmid, Ralph; Aebersold, Daniel; Gautschi, Oliver; Nagel, Wolfgang; Töpfer, Michael; ... (2015). Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. The lancet oncology, 16(16), pp. 1651-1658. Elsevier 10.1016/S1470-2045(15)00208-9
Pless, Miklos; Stupp, Roger; Ris, Hans-Beat; Stahel, Rolf A; Weder, Walter; Thierstein, Sandra; Gerard, Marie-Aline; Xyrafas, Alexandros; Früh, Martin; Cathomas, Richard; Zippelius, Alfred; Roth, Arnaud; Bijelovic, Milorad; Ochsenbein, Adrian; Meier, Urs R; Mamot, Christoph; Rauch, Daniel; Gautschi, Oliver; Betticher, Daniel C; Mirimanoff, René-Olivier; ... (2015). Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet, 386(9998), pp. 1049-1056. Elsevier 10.1016/S0140-6736(15)60294-X
Riether, Carsten; Gschwend, T; Huguenin, Anne-Laure; Schürch, Christian; Ochsenbein, Adrian (2015). Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells. Leukemia, 29(8), pp. 1781-1785. Nature Publishing Group 10.1038/leu.2015.26
Riether, Carsten; Schürch, Christian; Flury, Christoph; Hinterbrandner, Magdalena; Drück, Linda; Huguenin, Anne-Laure; Baerlocher, Gabriela M.; Radpour, Ramin; Ochsenbein, Adrian (2015). Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling. Science translational medicine, 7(298), 298ra119. American Association for the Advancement of Science 10.1126/scitranslmed.aab1740
Mager, Lukas; Riether, Carsten; Schürch, Christian; Banz Wälti, Yara; Wasmer, Marie-Hélène Christin; Stuber Roos, Regula; Theocharides, Alexandre; Li, Xiaohong; Xia, Yu; Saito, Hirohisa; Nakae, Susumu; Baerlocher, Gabriela M.; Manz, Markus G; McCoy, Kathleen; Macpherson, Andrew; Ochsenbein, Adrian; Beutler, Bruce; Krebs, Philippe (2015). IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. Journal of clinical investigation, 125(7), pp. 2579-2591. American Society for Clinical Investigation 10.1172/JCI77347
Galli, Serena; Zlobec, Inti; Schürch, Christian; Perren, Aurel; Ochsenbein, Adrian; Banz Wälti, Yara (2015). CD47 protein expression in acute myeloid leukemia: A tissue microarray-based analysis. Leukemia research, 39(7), pp. 749-756. Elsevier 10.1016/j.leukres.2015.04.007
Trabanelli, Sara; Curti, Antonio; Lecciso, Mariangela; Salomé, Bérengère; Riether, Carsten; Ochsenbein, Adrian; Romero, Pedro; Jandus, Camilla (2015). CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis. Haematologica - the hematology journal, 100(7), e257-e260. Ferrata-Storti Foundation 10.3324/haematol.2014.119602
Hunger, Robert; Angermeier, Sarina; Seyed Jafari, Seyed Morteza; Ochsenbein, Adrian; Shafighi, Maziar (2015). A retrospective study of 1- versus 2-cm excision margins for cutaneous malignant melanomas thicker than 2 mm. Journal of the American Academy of Dermatology, 72(6), pp. 1054-1059. Elsevier 10.1016/j.jaad.2015.03.029
Kollár, Attila; Hewer, Ekkehard; Kellner-Weldon, Frauke; Ochsenbein, Adrian (2015). Complete pain relief after bevacizumab in a patient with neurofibromatosis type 2. Acta oncologica, 54(2), pp. 280-288. Acta Oncologica 10.3109/0284186X.2014.956185
Riether, Carsten; Schürch, Christian; Ochsenbein, Adrian (2015). Regulation of hematopoietic and leukemic stem cells by the immune system. Cell death and differentiation, 22(2), pp. 187-198. Nature Publishing Group 10.1038/cdd.2014.89
Gautschi, O.; Mach, N.; Rothschild, S.; Li, Qiyu; Stahel, R. A.; Zippelius, A.; Cathomas, R.; Früh, M.; Betticher, D. C.; Peters, S.; Rauch, D.; Feilchenfeldt, J.; Bubendorf, L.; Savic, S.; Jaggi, Rolf; Oppliger Leibundgut, Elisabeth; Largiadèr, Carlo Rodolfo; Brutsche, M.; Pilop, C.; Stalder, L.; ... (2015). Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clinical lung cancer, 16(5), pp. 358-365. Elsevier 10.1016/j.cllc.2015.02.007
Balmer, Maria L; Schürch, Christian; Saito, Yasuyuki; Geuking, Markus; Li, Hai; Cuenca, Miguelangel; Kovtonyuk, Larisa V; McCoy, Kathleen; Hapfelmeier, Siegfried; Ochsenbein, Adrian; Manz, Markus G; Slack, Emma; Macpherson, Andrew (2014). Microbiota-derived compounds drive steady-state granulopoiesis via MyD88/TICAM signaling. Journal of immunology, 193(10), pp. 5273-5283. American Association of Immunologists 10.4049/jimmunol.1400762
Jörger Messerli, Marianne; Baty, F; Früh, M; Stahel, R A; Betticher, D C; von Moos, Rodica; Ochsenbein, Adrian; Pless, M; Gautschi, O; Rothschild, S; Brauchli, P; Klingbiel, Dirk; Zappa, F; Brutsche, M (2014). Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung cancer, 85(2), pp. 306-313. Elsevier 10.1016/j.lungcan.2014.04.014
Schürch, Christian; Riether, Carsten; Ochsenbein, Adrian (2014). Cytotoxic CD8+ T cells stimulate hematopoietic progenitors by promoting cytokine release from bone marrow mesenchymal stromal cells. Cell stem cell, 14(4), pp. 460-472. Elsevier 10.1016/j.stem.2014.01.002
Lennerz, Volker; Gross, Stefanie; Gallerani, Elisa; Sessa, Cristiana; Mach, Nicolas; Boehm, Steffen; Hess, Dagmar; von Boehmer, Lotta; Knuth, Alexander; Ochsenbein, Adrian; Gnad-Vogt, Ulrike; Zieschang, Juergen; Forssmann, Ulf; Woelfel, Thomas; Kaempgen, Eckhart (2014). Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer immunology, immunotherapy, 63(4), pp. 381-394. Springer 10.1007/s00262-013-1516-5
Eisele, Günter; Wick, Antje; Eisele, Anna-Carina; Clément, Paul M; Tonn, Jörg; Tabatabai, Ghazaleh; Ochsenbein, Adrian; Schlegel, Uwe; Neyns, Bart; Krex, Dietmar; Langenegger, Simon Matthias; Nikkhah, Guido; Picard, Martin; Stupp, Roger; Wick, Wolfgang; Weller, Michael (2014). Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. Journal of neuro-oncology, 117(1), pp. 141-145. Springer 10.1007/s11060-014-1365-x
Weber, Benjamin; Schuster, Steffen; Zysset, Daniel; Rihs, Silvia; Dickgreber, Nina; Schürch, Christian; Riether, Carsten; Siegrist, Mark; Schneider, Christoph; Pawelski, Helga; Gurzeler, Ursina; Ziltener, Pascal; Genitsch, Vera; Tacchini-Cottier, Fabienne; Ochsenbein, Adrian; Hofstetter, Willy; Kopf, Manfred; Kaufmann, Thomas; Oxenius, Annette; Reith, Walter; ... (2014). TREM-1 deficiency can attenuate disease severity without affecting pathogen clearance. PLoS pathogens, 10(1), e1003900. Public Library of Science 10.1371/journal.ppat.1003900
Schürch, Christian; Riether, Carsten; Matter, Matthias S; Tzankov, Alexandar; Ochsenbein, Adrian (2012). CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression. Journal of clinical investigation, 122(2), pp. 624-38. Ann Arbor, Mich.: American Society for Clinical Investigation 10.1172/JCI45977
Zappa, Francesco; Droege, Cornelia; Betticher, Daniel; von Moos, Roger; Bubendorf, Lukas; Ochsenbein, Adrian; Gautschi, Oliver; Oppliger Leibundgut, Elisabeth; Froesch, Patrizia; Stahel, Rolf; Hess, Thomas; Rauch, Daniel; Schmid, Petra; Mayer, Michael; Crowe, Susanne; Brauchli, Peter; Ribi, Karin; Pless, Miklos; on behalf of the Swiss Group for Clinical Cancer Research (SAKK), (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). Lung cancer, 78(3), pp. 239-44. Amsterdam: Elsevier 10.1016/S1359-6349(09)71860-9
Riether, Carsten; Schürch, Christian; Ochsenbein, Adrian (2012). Modulating CD27 signaling to treat cancer. Oncoimmunology, 1(9), pp. 1604-1606. Austin, Tex.: Landes Bioscience 10.4161/onci.21425
Claus, Christina; Riether, Carsten; Schürch, Christian; Matter, Matthias S; Hilmenyuk, Tamara; Ochsenbein, Adrian (2012). CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer research, 72(14), pp. 3664-76. Birmingham, Ala.: American Association for Cancer Research AACR 10.1158/0008-5472.CAN-11-2791
Fahrner, René; Ochsenbein, Adrian; Schmid, Ralph A; Carboni, Giovanni L (2012). Long term survival after trimodal therapy in malignant pleural mesothelioma. Swiss medical weekly, 142, w13686. Muttenz: EMH Schweizerischer Ärzteverlag 10.4414/smw.2012.13686
Schoenewolf, Nicola L; Dummer, Reinhard; Mihic-Probst, Daniela; Moch, Holger; Simcock, Mathew; Ochsenbein, Adrian; Gillessen, Silke; Schraml, Peter; von Moos, Roger; Swiss Group for Clinical Cancer Research, (SAKK) (2012). Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques. Case reports in oncology, 5(2), pp. 280-9. Basel: Karger 10.1159/000339300
Schraml, Peter; von Teichman, Adriana; Mihic-Probst, Daniela; Simcock, Mathew; Ochsenbein, Adrian; Dummer, Reinhard; Michielin, Olivier; Seifert, Bettina; Schläppi, Marc; Moch, Holger; von Moos, Roger (2012). Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncology reports, 28(2), pp. 654-8. Athens: National Hellenic Research Foundation 10.3892/or.2012.1826
Matter, Matthias S; Hilmenyuk, Tamara; Claus, Christina; Marone, Romina; Schürch, Christian; Tinguely, Marianne; Terracciano, Luigi; Luther, Sanjiv A; Ochsenbein, Adrian (2011). Destruction of lymphoid organ architecture and hepatitis caused by CD4+ T cells. PLoS ONE, 6(9), e24772. Lawrence, Kans.: Public Library of Science 10.1371/journal.pone.0024772
Hofer, Silvia; Elandt, Katarzyna; Greil, Richard; Hottinger, Andreas F; Huber, Urs; Lemke, Dieter; Marosi, Christine; Ochsenbein, Adrian; Pichler, Josef; Roelcke, Ulrich; Weder, Patrik; Zander, Thilo; Wick, Wolfgang; Weller, Michael (2011). Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta oncologica, 50(5), pp. 630-5. Stockholm: Acta Oncologica 10.3109/0284186X.2011.572913
Mumprecht, Sabine Barbara; Schürch, Christian; Scherrer, Sandro; Claus, Christina; Ochsenbein, Adrian (2010). Chronic myelogenous leukemia maintains specific CD8(+) T cells through IL-7 signaling. European journal of immunology, 40(10), pp. 2720-2730. Weinheim: Wiley-VCH 10.1002/eji.201040404
Rothschild, S; Amrein, Michael; Riether, Carsten; Gautschi, O; Schuster, N; Li, Q; Savic, S; Schneider, M; Biaggi, C; Bubendorf, L; Brutsche, M; Zippelius, A; Zander, T; Betticher, D; Früh, M; Stahel, R; Cathomas, R; Rauch, Daniel; Pless, M; Ochsenbein, Adrian; ... (October 2017). CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09). Journal of thoracic oncology, 12(11S2), S1864-S1865. Elsevier
